TELK -- Telik, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (830)	1/10/2007 12:19:00 PM
From: zeta1961	Read Replies (1) of 887

I listened to the JPMorgan webcast to feed masachoistic needs.. Wick anticipates filing IND compound '58747'..solid tumor agent..it's an oral and IV formulation 2 others on tap but no IND guidance: -a dual aurora kinase inhibitor -Akt targetting agent for breast A-5 still accruing..They remain committed to Telcyta and hope that it'll find it's niche in earlier stage ovarian/lung cancers -Assist data from all 3 trials will be presented at upcoming scientific conferences P2 Telcyta triplicate in 1st line NSCLC will be presented at AACR..120 patient study Telintra..start cytopenia P2..

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next